Resivant Medical Welcomes Jeff Clark to Its Board, Aiming for Innovation in Medical Devices

Resivant Medical Welcomes Jeff Clark to Its Board

In a significant move for the future of medical innovation, Resivant Medical has appointed Jeff Clark, an esteemed leader in the medical device sector, to its Board of Directors. This decision, announced on March 26, 2025, by the company based in Akron, Ohio, comes as a strategic addition aimed at advancing the development of groundbreaking medical adhesive technology.

Jeff Clark brings an extensive background with over 30 years of experience in the industry. His previous role as the CEO of HyperBranch Medical Technology highlighted his capacity for leadership in medical innovation, where he successfully guided the development and commercialization of the Adherus AutoSpray Dural Sealant, a product that has made waves in the global market. Under Clark's guidance, HyperBranch grew and eventually attracted the interest of Stryker Corp, which acquired the company in 2018.

Moreover, Clark’s expertise does not stop there. His notable tenure at Closure Medical Corporation as Vice President of Research and Development saw him leading the team that developed Dermabond, the first FDA-approved topical skin adhesive. This foundation in developing life-changing medical products positions him as an invaluable asset to Resivant as it seeks to elevate its own offerings in the medical adhesive space.

Russ Donda, Chairman of the Board at Resivant Medical, expressed enthusiasm about Clark's appointment: "We are extremely pleased to welcome Jeff to our board. His extensive experience and deep understanding of surgical adhesive development and medical device commercialization will be essential as we strive to bring our innovative Cutiva™ adhesive platform to market. Our mission is not only to serve the U.S. healthcare market but also to extend our reach globally, helping patients everywhere."

The Cutiva adhesive platform is a game-changing innovation in the medical adhesive industry. Resivant's commitment to developing advanced adhesive technologies is further exemplified by its recent U.S. FDA 510(k) clearance for its two flagship products: the Cutiva™ Topical Skin Adhesive and the Cutiva PLUS™ Skin Closure System. Together, these products promise to enhance usability and performance for both healthcare professionals and patients, making significant advancements in skin closure methods.

The global market for skin closure, which encompasses both traditional and advanced surgical methods, was valued at approximately USD $14.4 billion in 2024. Experts anticipate continued and substantial growth in this area, indicating strong demand for innovative solutions like those pioneered by Resivant Medical. With Jeff Clark on board, the company is well-positioned to leverage this market potential and solidify its status as a frontrunner in medical adhesive technology.

As the medical field continues to evolve and embrace innovative technologies, the relationship between Resivant Medical and Jeff Clark signifies a promising step towards revolutionary advancements that could redefine how surgical and topical procedures are performed, ultimately improving patient outcomes.

In summary, with his vast experience and proven track record in medical device innovation, Jeff Clark’s strategic role at Resivant Medical is likely to catalyze further developments in the company’s quest to revolutionize medical adhesives, ensuring better future care for patients in the U.S. and beyond.

For more information about Resivant Medical and its innovative products, visit www.resivant.com.